High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer-Reference-Cited by-同舟云学术

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

Published:2010-05-06 Issue:3 Volume:12 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Staaf Johan,Jönsson Göran,Ringnér Markus,Vallon-Christersson Johan,Grabau Dorthe,Arason Adalgeir,Gunnarsson Haukur,Agnarsson Bjarni A,Malmström Per-Olof,Johannsson Oskar Th,Loman Niklas,Barkardottir Rosa B,Borg Åke

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr2568.pdf

Reference69 articles.

1. Jonkers J, Berns A: Oncogene addiction: sometimes a temporary slavery. Cancer Cell. 2004, 6: 535-538.

2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182. 10.1126/science.3798106.

3. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990, 8: 103-112.

4. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007, 369: 29-36. 10.1016/S0140-6736(07)60028-2.

5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005, 353: 1673-1684. 10.1056/NEJMoa052122.

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kataegis in clinical and molecular subgroups of primary breast cancer;npj Breast Cancer;2024-04-24

2. Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer;Breast Cancer Research;2024-02-07

3. The regulatory mechanisms of oncomiRs in cancer;Biomedicine & Pharmacotherapy;2024-02

4. Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer;npj Breast Cancer;2023-10-19

5. Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity;Breast Cancer Research;2023-10-07